Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants By midwayadmin|2020-05-15T15:34:56+00:00May 15th, 2020| Read More
D/C/F/TAF FDC Evaluated as a Fixed Dose Combination Regimen in Participants Switching from an Integrase Inhibitor who have Experienced Rapid Weight Gain By midwayadmin|2020-05-15T15:27:28+00:00May 15th, 2020| Read More
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With HIV-1 By midwayadmin|2020-05-15T15:18:14+00:00May 15th, 2020| Read More
A Phase 2/3 Study to Evaluate the Safety and Efficacy of GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced Subjects with HIV-1 Infection. By midwayadmin|2020-05-15T15:13:57+00:00May 15th, 2020| Read More
Study to Evaluate the Safety and Efficacy of Long-Acting Capsid Inhibitor GS-6207 in Combination With Other Antiretroviral Agents in People Living With HIV By midwayadmin|2020-05-15T15:08:12+00:00May 15th, 2020| Read More
Randomized, Double-blind, Efficacy, and Safety Study of Doravirine/Islatravir (DOR/ISL) in Treatment-naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection By midwayadmin|2020-05-15T15:04:15+00:00May 15th, 2020| Read More
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to MK-8591A Once-Daily in Participants with HIV-1 Virologically Suppressed on Biktarvy By midwayadmin|2020-11-03T20:00:39+00:00May 15th, 2020| Read More
A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to MK-8591A Once-Daily in participants with HIV-1 Virologically Suppressed on Antiretroviral Therapy (ART). By midwayadmin|2020-11-03T20:01:11+00:00May 15th, 2020| Read More
A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily Plus Ritonavir 100 mg Once Daily, Each in Combination With TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1 Infected Subjects By midwayadmin|2019-10-28T19:40:05+00:00October 28th, 2019| Read More
Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis By midwayadmin|2019-10-28T19:37:43+00:00October 28th, 2019| Read More
